National emphysema treatment trial state of the art genetics of emphysema

Proceedings of the American Thoracic Society

Volumn 5, Issue 4, 2008, Pages 486-493

  Hersh, Craig P ^a,b   DeMeo, Dawn L ^a   Silverman, Edwin K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CHANNING LABORATORY   (United States)

Author keywords

1 antitrypsin deficiency; Chronic obstructive pulmonary disease; Genetic linkage; Single nucleotide polymorphism

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DNA MICROARRAY; EMPHYSEMA; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; PHENOTYPE; REVIEW;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); PHENOTYPE; PULMONARY EMPHYSEMA; RISK FACTORS; VARIATION (GENETICS);

EID: 43449107708     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200706-078ET     Document Type: Review

References (125)

1. Knudson RJ. James Jackson, Jr., the young pulmonologist who described familial emphysema: an historical footnote. Chest 1985;87:673-676.
2. Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. Scand J Clin Lab Invest 1963;15:132-140.
3. Celedón JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, Reilly JJ, Kwiatkowski DJ, Chapman HA, Laird N, et al. The transforming growth factor-b1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004;13:1649-1656.
4. DeMeo DL, Mariani TJ, Lange C, Srisuma S, Litonjua AA, Celedón JC, Lake SL, Reilly JJ, Chapman HA, Mecham BH, et al. The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am J Hum Genet 2006;78:253-264.
5. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978;118:1-120.
6. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 2005;6:287-298.
7. Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006;173:1222-1228.
8. Lomas DA. The selective advantage of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2006;173:1072-1077.
9. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992;357:605-607.
10. Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: molecular pathophysiology. Thorax 2004;59:529-535.
11. Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J 2005;26:67-76.
12. Lee JH, Brantly M. Molecular mechanisms of alpha1-antitrypsin null alleles. Respir Med 2000;94:S7-S11.
13. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59:259-264.
14. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest 1986;89:370-373.
15. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in falphag1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004;59:843-849.
16. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160:1468-1472.
17. 1-antitrypsin deficiency? Eur Respir J 1997;10:2260-2263.
18. 1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158:49-59.
19. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-900.
20. Cassina PC, Teschler H, Konietzko N, Theegarten D, Stamatis G. Two-year results after lung volume reduction surgery in alpha1-antitrypsin deficiency versus smoker's emphysema. Eur Respir J 1998;12:1028-1032.
21. Gelb AF, McKenna RJ, Brenner M, Fischel R, Zamel N. Lung function after bilateral lower lobe lung volume reduction surgery for alpha1-antitrypsin emphysema. Eur Respir J 1999;14:928-933.
22. Tutic M, Bloch KE, Lardinois D, Brack T, Russi EW, Weder W. Long-term results after lung volume reduction surgery in patients with alpha1-antitrypsin deficiency. J Thorac Cardiovasc Surg 2004;128:408-413.
23. Stoller JK, Gildea TR, Ries AL, Meli YM, Karafa MT. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg 2007;83:241-251.
24. Silverman EK, Mosley JD, Palmer LJ, Barth M, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, et al. Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes. Hum Mol Genet 2002;11:623-632.
25. Silverman EK, Palmer LJ, Mosley JD, Barth M, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, et al. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002;70:1229-1239.
26. Palmer LJ, Celedon JC, Chapman HA, Speizer FE, Weiss ST, Silverman EK. Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Mol Genet 2003;12:1199-1210.
27. DeMeo DL, Celedon JC, Lange C, Reilly JJ, Chapman HA, Sylvia JS, Speizer FE, Weiss ST, Silverman EK. Genome-wide linkage of forced mid-expiratory flow in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:1294-1301.
28. Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, O'Donnell WJ, Reilly JJ, Ginns L, Mentzer S, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770-1778.
29. Hersh CP, DeMeo DL, Raby BA, Litonjua AA, Sylvia JS, Sparrow D, Reilly JJ, Silverman EK. Genetic linkage and association analysis of COPD-related traits on chromosome 8p. COPD 2006;3:189-194.
30. Malhotra A, Peiffer AP, Ryujin DT, Elsner T, Kanner RE, Leppert MF, Hasstedt SJ. Further evidence for the role of genes on chromosome 2 and chromosome 5 in the inheritance of pulmonary function. Am J Respir Crit Care Med 2003;168:556-561.
31. Hersh CP, DeMeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatkowski D, Laird N, Sylvia JS, Sparrow D, Speizer FE, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 2005;33:71-78.
32. Bell B, Rose CL, Damon H. The Normative Aging Study: an interdisciplinary and longitudinal study of health and aging. Aging Hum Dev 1972;3:5-17.
33. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994;3:421-428.
34. Hirschhorn JN, Altshuler D. Once and again-issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002;87:4438-4441.
35. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-309.
36. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-872.
37. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004;125:754-765.
38. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783-2787.
39. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-228.
40. Wu L, Chau J, Young RP, Pokorny V, Mills GD, Hopkins R, McLean L, Black PN. Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 2004;59:126-129.
41. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Nolte IM, Boezen HM. Decorin and TGF-beta1 polymorphisms and development of COPD in a general population. Respir Res 2006;7:89.
42. Yoon HI, Silverman EK, Lee HW, Yoo CG, Lee CT, Chung HS, Kim YW, Han SK, Shim YS, Yim JJ. Lack of association between COPD and transforming growth factor-beta1 (TGFB1) genetic polymorphisms in Koreans. Int J Tuberc Lung Dis 2006;10:504-509.
43. Ogawa E, Ruan J, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. Transforming growth factor-beta1 polymorphisms, airway responsiveness and lung function decline in smokers. Respir Med 2007;101:938-943.
44. Mariani TJ, Reed JJ, Shapiro SD. Expression profiling of the developing mouse lung: insights into the establishment of the extracellular matrix. Am J Respir Cell Mol Biol 2002;26:541-548.
45. Spira A, Beane J, Pinto-Plata V, Kadar A, Liu G, Shah V, Celli B, Brody JS. Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol 2004;31:601-610.
46. Hersh CP, DeMeo DL, Silverman EK. Chronic obstructive pulmonary disease. In: Silverman EK, Shapiro SD, Lomas DA, Weiss ST, editors. Respiratory genetics. New York: Hodder Arnold; 2005. pp. 253-296.
47. Shapiro SD. Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Eur Respir J 2007;29:375-378.
48. Zhu G, Warren L, Aponte J, Gulsvik A, Bakke P, The International COPD Genetics Network (ICGN) Investigators, Anderson WH, Lomas DA, Silverman EK, Pillai SG. The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med 2007;176:167-173.
49. Chappell S, Daly L, Morgan K, Baranes TG, Roca J, Rabinovich R, Millar A, Donnelly SC, Keatings V, MacNee W, et al. The SERPINE2 gene and chronic obstructive pulmonary disease. Am J Hum Genet 2006;79:184-186 (author reply: 186-187).
50. Seersholm N, Wilcke JTR, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in a1-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000;161:81-84.
51. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Paré PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001;163:469-473.
52. Minematsu N, Nakamura H, Tateno H, Nakajima T, Yamaguchi K. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001;289:116-119.
53. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000;66:187-195.
54. Baranova H, Perriot J, Albuisson E, Ivaschenko T, Baranov VS, Hemery B, Mouraire P, Riol N, Malet P. Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis. Hum Genet 1997;99:822-826.
55. Huang S-L, Su C-H, Chang S-C. Tumor necrosis factor-α gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997;156:1436-1439.
56. Hersh CP, DeMeo DL, Lazarus R, Celedón JC, Raby BA, Benditt JO, Criner G, Make B, Martinez FJ, Scanlon PD, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:977-984.
57. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-2073.
58. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
59. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in a1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med 2004;170:1172-1178.
60. Muller NL, Coxson H. Chronic obstructive pulmonary disease. 4: imaging the lungs in patients with chronic obstructive pulmonary disease. Thorax 2002;57:982-985.
61. Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, Mishima M. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005;172:1378-1382.
62. Demeo DL, Hersh CP, Hoffman EA, Litonjua AA, Lazarus R, Sparrow D, Benditt JO, Criner G, Make B, Martinez FJ, et al. Genetic determinants of emphysema distribution in the National Emphysema Treatment Trial. Am J Respir Crit Care Med 2007;176:42-48.
63. Corbett E, Glaisyer H, Chan C, Madden B, Khaghani A, Yacoub M. Congenital cutis laxa with a dominant inheritance and early onset emphysema. Thorax 1994;49:836-837.
64. Tassabehji M, Metcalfe K, Hurst J, Ashcroft GS, Kielty C, Wilmot C, Donnai D, Read AP, Jones CJ. An elastin gene mutation producing abnormal tropoelastin and abnormal elastic fibres in a patient with autosomal dominant cutis laxa. Hum Mol Genet 1998;7:1021-1028.
65. Zhang MC, He L, Giro M, Yong SL, Tiller GE, Davidson JM. Cutis laxa arising from frameshift mutations in exon 30 of the elastin gene (ELN). J Biol Chem 1999;274:981-986.
66. Kelleher CM, Silverman EK, Broekelmann T, Litonjua AA, Hernandez M, Sylvia JS, Stoler J, Reilly JJ, Chapman HA, Speizer FE, et al. A functional mutation in the terminal exon of elastin in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2005;33:355-362.
67. Hersh CP, DeMeo DL, Reilly JJ, Silverman EK. Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgery. Respir Res 2007;8:59.
68. The International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-796.
69. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389.
70. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, Wichmann HE, Meitinger T, Hunter D, Hu FB, et al. A common genetic variant is associated with adult and childhood obesity. Science 2006;312:279-283.
71. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-885.
72. Hegab AE, Sakamoto T, Saitoh W, Massoud HH, Massoud HM, Hassanein KM, Sekizawa K. Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 2004;126:1832-1839.
73. Cotch MF, Beaty TH, Munoz A, Cohen BH. Estimating familial aggregation while adjusting for covariates: application to pulmonary function data from black and white sibships. Ann Epidemiol 1992;2:317-324.
74. Whitfield KE, Wiggins SA, Belue R, Brandon DT. Genetic and environmental influences on forced expiratory volume in African Americans: the Carolina African-American Twin Study of Aging. Ethn Dis 2004;14:206-211.
75. Guo X, Lin HM, Lin Z, Montano M, Sansores R, Wang G, DiAngelo S, Pardo A, Selman M, Floros J. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001;18:482-490.
76. National Heart, Lung, and Blood Institute. Morbidity & mortality: 2002 chart book on cardiovascular, lung, and blood diseases. Bethesda (MD): National Institutes of Health; 2002.
77. Adams SG, Anzueto A, Pugh JA, Lee S, Hazuda HP. Mexican American elders have similar severities of COPD despite less tobacco exposure than European American elders. Respir Med 2006;100:1966-1972.
78. Ning W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP, Otterbein SL, Song R, Hayashi S, Zhou Z, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004;101:14895-14900.
79. Golpon HA, Coldren CD, Zamora MR, Cosgrove GP, Moore MD, Tuder RM, Geraci MW, Voelkel NF. Emphysema lung tissue gene expression profiling. Am J Respir Cell Mol Biol 2004;31:595-600.
80. Poller W, Faber JP, Scholz S, Weidinger S, Bartholome K, Olek K, Eriksson S. Mis-sense mutation of alpha 1-antichymotrypsin gene associated with chronic lung disease. Lancet 1992;339:1538.
81. Poller W, Faber JP, Weidinger S, Tief K, Scholz S, Fischer M, Olek K, Kirchgesser M, Heidtmann HH. A leucine-to-proline substitution causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 1993;17:740-743.
82. Ishii T, Matsuse T, Teramoto S, Matsui H, Hosoi T, Fukuchi Y, Ouchi Y. Association between alpha-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease. Eur J Clin Invest 2000;30:543-548.
83. Sandford AJ, Chagani T, Weir TD, Pare PD. Alpha 1-antichymotrypsin mutations in patients with chronic obstructive pulmonary disease. Dis Markers 1998;13:257-260.
84. Benetazzo MG, Gile LS, Bombieri C, Malerba G, Massobrio M, Pignatti PF, Luisetti M. alpha 1-antitrypsin TAQ I polymorphism and alpha 1-antichymotrypsin mutations in patients with obstructive pulmonary disease. Respir Med 1999;93:648-654.
85. Ho L-I, Harn H-J, Chen C-J, Tsai N-M. Polymorphism of the β2-adrenoceptor in COPD in Chinese subjects. Chest 2001;120:1493-1499.
86. Joos L, Weir TD, Connett JE, Anthonisen NR, Woods R, Pare PD, Sandford AJ. Polymorphisms in the beta2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax 2003;58:703-707.
87. Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. Eur Respir J 2006;27:682-688.
88. Matsushita I, Hasegawa K, Nakata K, Yasuda K, Tokunaga K, Keicho N. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2002;291:17-22.
89. Hu RC, Xu YJ, Zhang ZX, Ni W, Chen SX. Correlation of HDEFB1 polymorphism and susceptibility to chronic obstructive pulmonary disease in Chinese Han population. Chin Med J (Engl) 2004;117:1637-1641.
90. Wallace AM, He JQ, Burkett KM, Ruan J, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study. Respir Res 2006;7:76.
91. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997;350:630-633.
92. Xiao D, Wang C, Du MJ, Pang BS, Zhang HY, Xiao B, Liu JZ, Weng XZ, Su L, Christiani DC. Relationship between polymorphisms of genes encoding microsomal epoxide hydrolase and glutathione S-transferase P1 and chronic obstructive pulmonary disease. Chin Med J (Engl) 2004;117:661-667.
93. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A, Yamakido M. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med 2000;5:49-53.
94. Takeyabu K, Yamaguchi E, Suzuki I, Nishimura M, Hizawa N, Kamakami Y. Gene polymorphism for microsomal epoxide hydrolase and susceptibility to emphysema in a Japanese population. Eur Respir J 2000;15:891-894.
95. Yim JJ, Park GY, Lee CT, Kim YW, Han SK, Shim YS, Yoo CG. Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1. Thorax 2000;55:121-125.
96. Horne SL, Cockcroft DW, Dosman JA. Possible protective effect against chronic obstructive airways disease by the GC2 allele. Hum Hered 1990;40:173-176.
97. Schellenberg D, Paré PD, Weir TD, Spinelli JJ, Walker BAM, Sandford AJ. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998;157:957-961.
98. Ishii T, Keicho N, Teramoto S, Azuma A, Kudoh S, Fukuchi Y, Ouchi Y, Matsuse T. Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis. Eur Respir J 2001;18:753-757.
99. Ito I, Nagai S, Hoshino Y, Muro S, Hirai T, Tsukino M, Mishima M. Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest 2004;125:63-70.
100. Kauffmann F, Kleisbauer JP, Cambon-De-Mouzon A, Mercier P, Constans J, Blanc M, Rouch Y, Feingold N. Genetic markers in chronic air-flow limitation: a genetic epidemiologic study. Am Rev Respir Dis 1983;127:263-269.
101. Kasuga I, Pare PD, Ruan J, Connett JE, Anthonisen NR, Sandford AJ. Lack of association of group specific component haplotypes with lung function in smokers. Thorax 2003;58:790-793.
102. Harrison DJ, Cantlay AM, Rae F, Lamb D, Smith CA. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol 1997;16:356-360.
103. Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J 2004;23:818-824.
104. He J-Q, Ruan J, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am J Respir Crit Care Med 2002;166:323-328.
105. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 1999;54:693-696.
106. Yim JJ, Yoo CG, Lee CT, Kim YW, Han SK, Shim YS. Lack of association between glutathione S-transferase P1 polymorphism and COPD in Koreans. Lung 2002;180:119-125.
107. Guenegou A, Leynaert B, Benessiano J, Pin I, Demoly P, Neukirch F, Boczkowski J, Aubier M. Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample: results from the European Community Respiratory Health Survey (ECRHS), France. J Med Genet 2006;43:e43.
108. Nakayama K, Kikuchi A, Yasuda H, Ebihara S, Sasaki T, Ebihara T, Yamaya M. Heme oxygenase-1 gene promoter polymorphism and decline in lung function in Japanese men. Thorax 2006;61:921.
109. Zhou M, Huang SG, Wan HY, Li B, Deng WW, Li M. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 2004;117:1481-1484.
110. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002;11:569-576.
111. Juul K, Tybjaerg-Hansen A, Marklund S, Lange P, Nordestgaard BG. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:858-864.
112. Young RP, Hopkins R, Black PN, Eddy C, Wu L, Gamble GD, Mills GD, Garrett JE, Eaton TE, Rees MI. Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax 2006;61:394-399.
113. Seifart C, Plagens A, Brodje D, Muller B, von Wichert P, Floros J. Surfactant protein B intron 4 variation in German patients with COPD and acute respiratory failure. Dis Markers 2002;18:129-136.
114. Su ZG, Wen FQ, Feng YL, Xiao M, Wu XL. Transforming growth factor-beta1 gene polymorphisms associated with chronic obstructive pulmonary disease in Chinese population. Acta Pharmacol Sin 2005;26:714-720.
115. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:420-422.
116. Matheson MC, Ellis JA, Raven J, Walters EH, Abramson MJ. Association of IL8, CXCR2 and TNF-alpha polymorphisms and airway disease. J Hum Genet 2006;51:196-203.
117. Higham MA, Pride NB, Alikhan A, Morrell NW. Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000;15:281-284.
118. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. Neither IL-1beta, IL-1 receptor antagonist, nor TNF-alpha polymorphisms are associated with susceptibility to COPD. Respir Med 2000;94:847-851.
119. Patuzzo C, Gile LS, Zorzetto M, Trabetti E, Malerba G, Pignatti PF, Luisetti M. Tumor necrosis factor gene complex in COPD and disseminated bronchiectasis. Chest 2000;117:1353-1358.
120. Ferrarotti I, Zorzetto M, Beccaria M, Gile LS, Porta R, Ambrosino N, Pignatti PF, Cerveri I, Pozzi E, Luisetti M. Tumour necrosis factor family genes in a phenotype of COPD associated with emphysema. Eur Respir J 2003;21:444-449.
121. Chierakul N, Wongwisutikul P, Vejbaesya S, Chotvilaiwan K. Tumor necrosis factor-alpha gene promoter polymorphism is not associated with smoking-related COPD in Thailand. Respirology 2005;10:36-39.
122. Hegab AE, Sakamoto T, Saitoh W, Nomura A, Ishii Y, Morishima Y, Iizuka T, Kiwamoto T, Matsuno Y, Massoud HH, et al. Polymorphisms of TNFalpha, IL1beta, and IL1RN genes in chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2005;329:1246-1252.
123. Jiang L, He B, Zhao MW, Ning LD, Li XY, Yao WZ. Association of gene polymorphisms of tumour necrosis factor-alpha and interleukin-13 with chronic obstructive pulmonary disease in Han nationality in Beijing. Chin Med J (Engl) 2005;118:541-547.
124. Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 2005;21:157-165.
125. Ruse CE, Hill MC, Tobin M, Neale N, Connolly MJ, Parker SG, Wardlaw AJ. Tumour necrosis factor gene complex polymorphisms in chronic obstructive pulmonary disease. Respir Med 2007;101:340-344.